RxDoctor Payments Data

Jesus Tovar, MD

Hospitalist · Lexington, KYNPI 1801059399

Payments from drug & device makers

$267in general payments, 2019–2025

Across 14 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$100
  • Neuronetics, Inc.$29
  • Braeburn Inc.$27
  • Takeda Pharmaceuticals U.S.A., Inc.$27
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$24
  • UCB, Inc.$19
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$267100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$267 in reported general payments places this provider in the 70th percentile of 258 hospitalist providers in Kentucky.

See all hospitalist providers in Kentucky

Medicare billing

Part B allowed, 2024
$143,704
Medicare patients
363
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban407$116,532
FarxigaDapagliflozin Propanediol187$51,061
XifaxanRifaximin38$44,940
OzempicSemaglutide34$35,114
EntrestoSacubitril/Valsartan66$20,862
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,192
Lagevrio (Eua)Molnupiravir18$18,040
JardianceEmpagliflozin59$17,001
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$14,962
JanuviaSitagliptin Phosphate48$13,275
RytaryCarbidopa/Levodopa24$10,715
MovantikNaloxegol Oxalate37$8,595
LinzessLinaclotide15$8,551
DapagliflozinDapagliflozin Propanediol26$7,908
VascepaIcosapent Ethyl53$7,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$116,532407 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$24$44,94038 claims
MerckLagevrio (Eua), Januvia$15$31,31566 claims
AbbVieLinzess, Restasis$100$14,76728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 258 hospitalist providers in Kentucky.

Other hospitalist in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →